Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03208725
Other study ID # OPP1131320
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date November 30, 2016
Est. completion date October 31, 2020

Study information

Verified date May 2020
Source University of Oxford
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The CHAIN Network aims to identify modifiable biomedical and social factors driving the greatly increased risk of mortality among young undernourished children admitted to hospital with acute illness, as inpatients and after discharge. The study will inform priorities, risks and targeting for multi-faceted interventional trials.

CHAIN is a multi-centre cohort study with a nested case control analysis of stored biological samples. Study sites are located in Africa and South Asia. Children will be recruited at admission to hospital, stratified by nutritional status. Exposures will be assessed at admission, during hospitalisation, at discharge, and at two time points after discharge. The main outcomes of interest are mortality, re-admission to hospital and failure of nutritional recovery up to 180 days after discharge. To determine community health norms, an additional sample of children living in the same communities will be enrolled and assessed at one time point only.


Description:

Despite an overall reduction of child mortality in LMICs, acutely-ill undernourished children continue to have a greatly elevated risk of death, both during hospitalisation and following discharge. However, we currently lack robust evidence for their management. Factors underlying the risks of mortality may relate to the acute illness itself, to children's longer term health trajectories, or to the home nutritional and care environment. The ultimate goal of the CHAIN Network is to identify and prioritize actionable intervention targets to reduce mortality among acutely ill undernourished children.

CHAIN's initial aim is to better understand the characteristics that determine increased risk of mortality in this vulnerable population, whether biological (related to infection, immunity and metabolism), nutritional (intake and anthropometry), health system factors (affecting management and discharge) or behavioural (community/caregiver interactions). CHAIN brings clinicians and scientists together from a variety of high-burden settings in Africa and South Asia. CHAIN will establish prospective cohorts of acutely ill young children across different geographies with differing population, social and environmental characteristics (stunted vs. wasting, rural vs. urban and presence of risk factors such as malaria and HIV).

Eight sites will be involved, including three hospitals in Kenya (Kilifi County, Migori County and Mbagathi District), two in Bangladesh (Matlab and the icddr,b Dhaka), and one in each of Uganda (Mulago), Malawi (Queen Elizabeth Community Hospital), Pakistan (Civil Hospital Karachi) and in West Africa (TBA). Site will enroll children at admission to hospital, and assess their clinical, social and economic status at admission, during hospitalisation, at discharge and during follow up for 180 days after discharge. The sites will also enrol children from the community to determine community norms (where ill and undernourished children would be expected to typically recover to). Protocols and procedures will be carefully harmonised across sites.

Children aged 2 months to 2 years admitted to hospital will be considered for inclusion and enrolment stratified by nutritional status. Following informed consent, baseline data of prognostic importance, including demographic and social information, a detailed clinical examination, anthropometry and measurement of vital signs, including pulse oximetry, will be collected using a standard proforma. A research blood sample will be collected together with the routine clinical blood draw to minimize the patient's discomfort. Rectal swabs and faecal sample will also be obtained from all children.

During admission, care will be provided according to WHO and national guidelines. Children will be reviewed daily and clinical features, progress and treatment received recorded on a structured case report form. In the event of death in hospital, a standard audit questionnaire will be completed. During admission, primary caregivers, usually the mother, will be interviewed screened for mental health problems. At discharge, anthropometry, a clinical assessment and blood, rectal swab and whole stool collected. Families will be linked with chronic care services where needed.

A home visit will be conducted for all participants, the GPS location recorded. Information homestead infrastructure, water and sanitation, population, livelihood, child care and socioeconomic characteristics. Children will be followed up at 45, 90 and 180 days after discharge. A health questionnaire will document health and social events, and dietary intake. Anthropometry, and faecal and blood samples collected.

Caregivers will be asked to attend the study hospital should the caregiver believes they may require hospitalisation. Study participants who are re-admitted to hospital will undergo standardised clinical assessment including history, examination and sample collection. In the event of death occurring outside the study hospital, a standard verbal autopsy (VA) will be completed by trained staff within 28 days of becoming aware of a death. VAs along with all available information will be used to ascribe causes of death.

Community participants will be invited to the study clinic for assessment. Following informed consent, they will have a clinical examination, anthropometry, blood and stool samples as children who are admitted. Children requiring non-urgent medical care will be eligible for inclusion as community participants but will be given basic treatment in the study clinic and/or referred to appropriate treatment centres. Study staff will refer community participants with incomplete vaccination or requiring care for chronic conditions as needed.

Several domains of exposure will be assessed: demographic, nutrition and metabolism; acute and chronic conditions; community-acquired and nosocomial infections (including antimicrobial resistance); gut function & dysbiosis; inflammation; responses to treatment; and the home care environment.

Successful design of an intervention package to address post-discharge child mortality will require attention social and economic agency and vulnerability, access and interactions with health services, and ethical considerations. A qualitative sub-study will examine these factors in context in rural and urban sites in Kenya and Bangladesh to identify critical social limitations and potential approaches to intervention. These data will inform the network's development, piloting, and implementation of interventions.

Additional sub-studies at a subset of sites will also examine in more detail the diagnosis and role of TB; and changes in functional immune responses; body composition and neurodevelopment during follow up.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 4335
Est. completion date October 31, 2020
Est. primary completion date January 31, 2020
Accepts healthy volunteers No
Gender All
Age group 2 Months to 23 Months
Eligibility Inclusion criteria (hospitalized participants):

- Children 2 months-23 months.

- Admitted to hospital.

- Planning to remain within the hospital catchment area and willing to come for specified visits during the 6 month follow up period.

- Parent or guardian consents on child's behalf.

Inclusion criteria (community participants):

- Aged 2 to 23 months

- Living in the same community as the acutely ill children recruited.

- Not having an acute illness requiring hospital admission

- Absence of known, but untreated HIV or TB

- Not admitted to hospital within the last 14 days

- Not previously included in the study

- Parent or guardian consents on child's behalf.

Exclusion Criteria (all participants):

- Requiring immediate resuscitation at admission to hospital*

- Unable to tolerate oral feeds while in his/her usual state of health

- Underlying terminal illness that in the opinion of the treating physician is likely to lead to death within 6 months (e.g., cancer, congenital heart disease)

- Diagnosed with a condition that in the opinion of the treating physician is likely to require surgery within 6 months

- Diagnosed chromosomal abnormality (syndromically or genetically diagnosed abnormality)

- Primary reason for admission is poisoning, trauma or a surgical condition

- Previously enrolled in this study

- Sibling currently or previously enrolled in this study

(* children requiring resuscitation will be defined as those with on-going cardiac or pulmonary arrest or judged to be peri-arrest by the attending physician)

Study Design


Locations

Country Name City State
Bangladesh ICDDR,B Dhaka Hospital Dhaka
Bangladesh Matlab Hospital Dhaka Chittagong
Kenya Kilifi County Hospital Kilifi
Kenya Migori County Hospital Migori
Kenya Mbagathi District Hospital Nairobi
Malawi Queen Elizabeth Central Hospital Blantyre
Pakistan Civil Hospital Karachi Karachi
Uganda Mulago Hospital Kampala

Sponsors (11)

Lead Sponsor Collaborator
University of Oxford Aga Khan University, International Centre for Diarrhoeal Disease Research, Bangladesh, KEMRI-Wellcome Trust Collaborative Research Program, Kenya Medical Research Institute, Makerere University, Oregon Health and Science University, The Hospital for Sick Children, University of Amsterdam, University of Malawi, University of Washington

Countries where clinical trial is conducted

Bangladesh,  Kenya,  Malawi,  Pakistan,  Uganda, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mortality Assessed using clinical and civil records and verbal autopsy Up to 30 days after admission to hospital
Primary Mortality Assessed using clinical and civil records and verbal autopsy Up to 180 days after discharge from hospital
Secondary Rehospitalization Number of participants, assessed from direct observation or clinical records Up to 180 days after discharge from hospital
Secondary Change in weight-for-height z-score Post-discharge growth Up to 180 days after discharge from hospital
Secondary Change in length-for-age z-score Post-discharge growth Up to 180 days after discharge from hospital
Secondary Change in mid-upper arm circumference Post-discharge growth Up to 180 days after discharge from hospital
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3